Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children

Pediatrics

Volumn 128, Issue 4, 2011, Pages 723-728

  Finkelstein, Yaron ^a,b,c   Soon, Gordon S ^a,b   Acuna, Patrick ^c   George, Mathew ^c   Pope, Elena ^a,b   Ito, Shinya ^a,b   Shear, Neil H ^a,b   Koren, Gideon ^a,b   Shannon, Michael W ^c   Garcia Bournissen, Facundo ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adverse drug reactions; Children; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CARBAMAZEPINE; CORTICOSTEROID; ERYTHROMYCIN; ETHOSUXIMIDE; IMMUNOGLOBULIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SULFAMETHOXAZOLE; ZONISAMIDE;

ADOLESCENT; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHILD; CLINICAL FEATURE; CONJUNCTIVITIS; CORNEA DISEASE; DISEASE COURSE; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HYPOPIGMENTATION; INFANT; KERATITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOPLASMA PNEUMONIA; PEDIATRIC HOSPITAL; PHIMOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCAR FORMATION; SCHOOL CHILD; SCLEROSING CHOLANGITIS; STEVENS JOHNSON SYNDROME; STRIDOR; TOXIC EPIDERMAL NECROLYSIS; UNITED STATES; UVEITIS; VEIN THROMBOSIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; RECURRENCE; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053534834     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-3322     Document Type: Article

References (30)

1. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123-129
2. Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med. 2009;36(1):22-32
3. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153 (Pubitemid 30637181)
4. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2). Available at: www.pediatrics.org/ cgi/content/full/123/2/e297
5. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181-200 (Pubitemid 46074234)
6. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-1607
7. Roujeau JC, Gelard K, Bensussan A. Epidermal necrolysis: mechanisms of keratinocyte apoptosis [in French]. Med Sci (Paris). 2006;22(2):188-191 (Pubitemid 43242076)
8. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43-47 (Pubitemid 20040979)
9. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns. 2010;36(2):152-163
10. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134-1138
11. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44 (Pubitemid 350249390)
12. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769-773 (Pubitemid 26280728)
13. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf. 2002;25(13):965-972 (Pubitemid 35252720)
14. Knowles S, Shear NH. Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009;22(5):441-451
15. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol. 2000;27(10):2494-2497
16. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 2003;112(6 pt 1):1430-1436 (Pubitemid 37523435)
17. Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr. 2009;21(4):505-510
18. Lin LC, Lai PC, Yang SF, Yang RC. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci. 2009;25(2):82-86
19. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58(4):504-510 (Pubitemid 40645392)
20. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847-853
21. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96 (Pubitemid 23029676)
22. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47(4):548-552
23. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35(5 pt 1):757-760 (Pubitemid 26389476)
24. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71(6):398-400 (Pubitemid 41769422)
25. Habib A, Pasha W, Raza N. Treatment of toxic epidermal necrolysis (TEN) with low dose intravenous immunoglobulin in child. J Coll Physicians Surg Pak. 2010;20:205-207
26. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int. 2002;14(4):143-150 (Pubitemid 34753025)
27. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30(10):2234-2240 (Pubitemid 37221857)
28. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. New Engl J Med. 1994;331(19):1272-1285 (Pubitemid 24333193)
29. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82(6):1826-1832 (Pubitemid 19054926)
30. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007;7(4):317-323